Medirom Healthcare Technologies Stock Current Valuation
| MRM Stock | USD 1.09 0.03 2.68% |
Valuation analysis of Medirom Healthcare helps investors to measure Medirom Healthcare's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. As of the 27th of December 2024, Enterprise Value Over EBITDA is likely to grow to 25.56. Also, Enterprise Value Multiple is likely to grow to 25.56. Fundamental drivers impacting Medirom Healthcare's valuation include:
Price Book 13.2383 | Enterprise Value 30.6 M | Enterprise Value Ebitda 27.3756 | Price Sales 0.0013 | Enterprise Value Revenue 0.6724 |
Overvalued
Today
Please note that Medirom Healthcare's price fluctuation is out of control at this time. Calculation of the real value of Medirom Healthcare is based on 3 months time horizon. Increasing Medirom Healthcare's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Medirom stock is determined by what a typical buyer is willing to pay for full or partial control of Medirom Healthcare Technologies. Since Medirom Healthcare is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Medirom Stock. However, Medirom Healthcare's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1.09 | Real 1.05 | Hype 1.15 |
The intrinsic value of Medirom Healthcare's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Medirom Healthcare's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Medirom Healthcare Technologies helps investors to forecast how Medirom stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Medirom Healthcare more accurately as focusing exclusively on Medirom Healthcare's fundamentals will not take into account other important factors: Medirom Healthcare Technologies Company Current Valuation Analysis
Medirom Healthcare's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Medirom Healthcare Current Valuation | 30.59 M |
Most of Medirom Healthcare's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Medirom Healthcare Technologies is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Medirom Current Valuation Driver Correlations
Understanding the fundamental principles of building solid financial models for Medirom Healthcare is extremely important. It helps to project a fair market value of Medirom Stock properly, considering its historical fundamentals such as Current Valuation. Since Medirom Healthcare's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Medirom Healthcare's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Medirom Healthcare's interrelated accounts and indicators.
Click cells to compare fundamentals
Medirom Current Valuation Historical Pattern
Today, most investors in Medirom Healthcare Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Medirom Healthcare's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current valuation growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Medirom Healthcare current valuation as a starting point in their analysis.
Medirom Healthcare Current Valuation |
| Timeline |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Medirom Healthcare Technologies has a Current Valuation of 30.59 M. This is 99.83% lower than that of the Health Care Providers & Services sector and 99.39% lower than that of the Health Care industry. The current valuation for all United States stocks is 99.82% higher than that of the company.
Medirom Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Medirom Healthcare's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Medirom Healthcare could also be used in its relative valuation, which is a method of valuing Medirom Healthcare by comparing valuation metrics of similar companies.Medirom Healthcare is currently under evaluation in current valuation category among its peers.
Medirom Healthcare Current Valuation Drivers
We derive many important indicators used in calculating different scores of Medirom Healthcare from analyzing Medirom Healthcare's financial statements. These drivers represent accounts that assess Medirom Healthcare's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Medirom Healthcare's important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 7.0B | 6.0B | 3.4B | 3.2B | 4.2B | 5.8B | |
| Enterprise Value | 8.2B | 6.4B | 5.1B | 5.1B | 7.7B | 7.7B |
Medirom Fundamentals
| Return On Equity | 1.47 | ||||
| Return On Asset | -0.036 | ||||
| Profit Margin | 0.02 % | ||||
| Operating Margin | (0.02) % | ||||
| Current Valuation | 30.59 M | ||||
| Shares Outstanding | 7.9 M | ||||
| Shares Owned By Insiders | 40.37 % | ||||
| Number Of Shares Shorted | 107.56 K | ||||
| Price To Book | 13.24 X | ||||
| Price To Sales | 0 X | ||||
| Revenue | 6.83 B | ||||
| Gross Profit | 1.42 B | ||||
| EBITDA | 310.08 M | ||||
| Net Income | 115.05 M | ||||
| Cash And Equivalents | 354.95 M | ||||
| Cash Per Share | 72.70 X | ||||
| Total Debt | 3.65 B | ||||
| Current Ratio | 0.36 X | ||||
| Book Value Per Share | 43.19 X | ||||
| Cash Flow From Operations | (631.74 M) | ||||
| Short Ratio | 0.71 X | ||||
| Earnings Per Share | (0.15) X | ||||
| Number Of Employees | 390 | ||||
| Beta | 0.009 | ||||
| Market Capitalization | 8.81 M | ||||
| Total Asset | 6.85 B | ||||
| Retained Earnings | 80.28 M | ||||
| Working Capital | (1.8 B) | ||||
| Net Asset | 6.85 B |
About Medirom Healthcare Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Medirom Healthcare Technologies's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Medirom Healthcare using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Medirom Healthcare Technologies based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Medirom Healthcare Piotroski F Score and Medirom Healthcare Altman Z Score analysis. You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
Is Health Care Providers & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Medirom Healthcare. If investors know Medirom will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Medirom Healthcare listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.582 | Earnings Share (0.15) | Revenue Per Share 1.4 K | Quarterly Revenue Growth (0.06) | Return On Assets (0.04) |
The market value of Medirom Healthcare is measured differently than its book value, which is the value of Medirom that is recorded on the company's balance sheet. Investors also form their own opinion of Medirom Healthcare's value that differs from its market value or its book value, called intrinsic value, which is Medirom Healthcare's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Medirom Healthcare's market value can be influenced by many factors that don't directly affect Medirom Healthcare's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Medirom Healthcare's value and its price as these two are different measures arrived at by different means. Investors typically determine if Medirom Healthcare is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Medirom Healthcare's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.